Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

N. Lawrence; A. Martin; G. Toner; M. Stockler; L. Buizen; D. Thomson; V. Gebski; M. Friedlander; A. Yeung; N. Wong; H. Gurney; M. Rosenthal; N. Singhal; G. Kichenadasse; S. Wong; C. Lewis; P. Vasey; P. Grimison

doi:10.1093/annonc/mdw313

Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

N. Lawrence, A. Martin, G. Toner, M. Stockler, L. Buizen, D. Thomson, V. Gebski, M. Friedlander, A. Yeung, N. Wong, H. Gurney, M. Rosenthal, N. Singhal, G. Kichenadasse, S. Wong, C. Lewis, P. Vasey, P. Grimison

Research output: Contribution to journal › Letter

1 Citation (Scopus)

Abstract

Germ cell tumours such as testicular cancer typically affect adolescent and young adult males. Since the introduction of cisplatin, outcomes for patients with advanced germ cell tumours have improved with cure rates exceeding 80% overall. However, outcomes are considerably worse for patients with intermediate or poor prognostic features with cure rates of only 79% and 48%, respectively.

Original language	English
Pages (from-to)	2302-2303
Number of pages	2
Journal	Annals of Oncology : Official Journal of the European Society for Medical Oncology
Volume	27
Issue number	12
DOIs	https://doi.org/10.1093/annonc/mdw313
Publication status	Published - 1 Dec 2016

Access to Document

10.1093/annonc/mdw313Licence: In Copyright

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)'. Together they form a unique fingerprint.

Cite this

Lawrence, N., Martin, A., Toner, G., Stockler, M., Buizen, L., Thomson, D., Gebski, V., Friedlander, M., Yeung, A., Wong, N., Gurney, H., Rosenthal, M., Singhal, N., Kichenadasse, G., Wong, S., Lewis, C., Vasey, P., & Grimison, P. (2016). Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology : Official Journal of the European Society for Medical Oncology, 27(12), 2302-2303. https://doi.org/10.1093/annonc/mdw313

Lawrence, N. ; Martin, A. ; Toner, G. ; Stockler, M. ; Buizen, L. ; Thomson, D. ; Gebski, V. ; Friedlander, M. ; Yeung, A. ; Wong, N. ; Gurney, H. ; Rosenthal, M. ; Singhal, N. ; Kichenadasse, G. ; Wong, S. ; Lewis, C. ; Vasey, P. ; Grimison, P. / Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours : updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). In: Annals of Oncology : Official Journal of the European Society for Medical Oncology. 2016 ; Vol. 27, No. 12. pp. 2302-2303.

@article{effdbc1740bc4bcbab43e6afa63a3519,

title = "Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)",

abstract = "Germ cell tumours such as testicular cancer typically affect adolescent and young adult males. Since the introduction of cisplatin, outcomes for patients with advanced germ cell tumours have improved with cure rates exceeding 80% overall. However, outcomes are considerably worse for patients with intermediate or poor prognostic features with cure rates of only 79% and 48%, respectively.",

author = "N. Lawrence and A. Martin and G. Toner and M. Stockler and L. Buizen and D. Thomson and V. Gebski and M. Friedlander and A. Yeung and N. Wong and H. Gurney and M. Rosenthal and N. Singhal and G. Kichenadasse and S. Wong and C. Lewis and P. Vasey and P. Grimison",

year = "2016",

month = dec,

day = "1",

doi = "10.1093/annonc/mdw313",

language = "English",

volume = "27",

pages = "2302--2303",

journal = "Annals of Oncology : Official Journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford Journals",

number = "12",

}

Lawrence, N, Martin, A, Toner, G, Stockler, M, Buizen, L, Thomson, D, Gebski, V, Friedlander, M, Yeung, A, Wong, N, Gurney, H, Rosenthal, M, Singhal, N, Kichenadasse, G, Wong, S, Lewis, C, Vasey, P & Grimison, P 2016, 'Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)', Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 27, no. 12, pp. 2302-2303. https://doi.org/10.1093/annonc/mdw313

Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours : updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). / Lawrence, N.; Martin, A.; Toner, G.; Stockler, M.; Buizen, L.; Thomson, D.; Gebski, V.; Friedlander, M.; Yeung, A.; Wong, N.; Gurney, H.; Rosenthal, M.; Singhal, N.; Kichenadasse, G.; Wong, S.; Lewis, C.; Vasey, P.; Grimison, P.

In: Annals of Oncology : Official Journal of the European Society for Medical Oncology, Vol. 27, No. 12, 01.12.2016, p. 2302-2303.

Research output: Contribution to journal › Letter

TY - JOUR

T1 - Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours

T2 - updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

AU - Lawrence, N.

AU - Martin, A.

AU - Toner, G.

AU - Stockler, M.

AU - Buizen, L.

AU - Thomson, D.

AU - Gebski, V.

AU - Friedlander, M.

AU - Yeung, A.

AU - Wong, N.

AU - Gurney, H.

AU - Rosenthal, M.

AU - Singhal, N.

AU - Kichenadasse, G.

AU - Wong, S.

AU - Lewis, C.

AU - Vasey, P.

AU - Grimison, P.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Germ cell tumours such as testicular cancer typically affect adolescent and young adult males. Since the introduction of cisplatin, outcomes for patients with advanced germ cell tumours have improved with cure rates exceeding 80% overall. However, outcomes are considerably worse for patients with intermediate or poor prognostic features with cure rates of only 79% and 48%, respectively.

AB - Germ cell tumours such as testicular cancer typically affect adolescent and young adult males. Since the introduction of cisplatin, outcomes for patients with advanced germ cell tumours have improved with cure rates exceeding 80% overall. However, outcomes are considerably worse for patients with intermediate or poor prognostic features with cure rates of only 79% and 48%, respectively.

UR - http://www.scopus.com/inward/record.url?scp=85040925777&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdw313

DO - 10.1093/annonc/mdw313

M3 - Letter

C2 - 27502724

AN - SCOPUS:85040925777

VL - 27

SP - 2302

EP - 2303

JO - Annals of Oncology : Official Journal of the European Society for Medical Oncology

JF - Annals of Oncology : Official Journal of the European Society for Medical Oncology

SN - 0923-7534

IS - 12

ER -

Lawrence N, Martin A, Toner G, Stockler M, Buizen L, Thomson D et al. Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology : Official Journal of the European Society for Medical Oncology. 2016 Dec 1;27(12):2302-2303. https://doi.org/10.1093/annonc/mdw313